Ameriprise
KRON

Ameriprise’s Kronos Bio KRON Stock Holding History

Ameriprise’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-133,015
Closed -$194K – 3958
2023
Q1 		$194K Buy
133,015
+37,166
+39% +$71.3K ﹤0.01% 3734
2022
Q4 		$155K Sell
95,849
-8,391
-8% -$19.3K ﹤0.01% 3751
2022
Q3 		$349K Buy
104,240
+5,330
+5% +$24.1K ﹤0.01% 3524
2022
Q2 		$360K Buy
98,910
+10,108
+11% +$45.8K ﹤0.01% 3508
2022
Q1 		$642K Buy
88,802
+47,548
+115% +$405K ﹤0.01% 3395
2021
Q4 		$561K Sell
41,254
-1,900
-4% -$29.7K ﹤0.01% 3479
2021
Q3 		$905K Buy
43,154
+3,737
+9% +$80.3K ﹤0.01% 3205
2021
Q2 		$944K Buy
39,417
+3,406
+9% +$86.2K ﹤0.01% 3251
2021
Q1 		$1.05M Sell
36,011
-7,779
-18% -$228K ﹤0.01% 3127
2020
Q4 		$1.31M Buy
+43,790
New +$1.37M ﹤0.01% 2967

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise's KRON Position: Q2 2023 in Review

Ameriprise sold out of Kronos Bio (KRON) in Q2 2023, closing a stake of 133,015 shares — an estimated $194K sold.

Ameriprise first reported a position in KRON in Q4 2020 and held it in 10 quarters. The position peaked at $1.31M in Q4 2020. 80 funds tracked by Wall St. Rank hold KRON as of Q2 2023.

  • Ameriprise reported no remaining Kronos Bio position as of Q2 2023 after selling out during the quarter.
  • Ameriprise sold 133,015 Kronos Bio shares in Q2 2023, an estimated $194K.
  • Ameriprise first reported a position in Kronos Bio in Q4 2020 and held it in 10 quarters.
  • Ameriprise's Kronos Bio position peaked at $1.31M in Q4 2020.
  • 80 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2023.

Based on Ameriprise's 13F filing for Q2 2023, filed 14 Aug 2023.